Journal profile · IMMUNOLOGY
Clinical and Experimental Vaccine Research
ISSN 2287-3651 · eISSN 2287-366X · Seoul : Korean Vaccine Society · Korea, Republic of
Clinical and Experimental Vaccine Research: CAS Zone 4 · Medicine (2025 upgraded edition); diamond open access (no APC); no APC; median 43 days to acceptance (61 articles, last 24 months); 47 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Clinical and Experimental Vaccine Research is published by Seoul : Korean Vaccine Society and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, Vaccine Coverage and Hesitancy and Influenza Virus Research Studies, together about 27.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Clin Exp Vaccine Res, the official English journal of Korean Vaccine Society and Korean Society for Zoonoses, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (http://www.ecevr.org) four times per year in 31 January, 30 April, 31 July and 31 October. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide.
From the journal's Aims & Scope
Research area (LetPub): IMMUNOLOGY
Editor-in-chief Ji YunPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named South Korea 30, United States 8, Japan 3, Sweden 2, Mainland China 1 (49 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- SARS-CoV-2 and COVID-19 ResearchMedicine11.4%
- Vaccine Coverage and HesitancySocial Sciences9.5%
- Influenza Virus Research StudiesMedicine6.4%
- Virology and Viral DiseasesMedicine6.3%
- vaccines and immunoinformatics approachesBiochemistry, Genetics and Molecular Biology6.1%
- Viral gastroenteritis research and epidemiologyMedicine5.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.8%
- Animal Disease Management and EpidemiologyAgricultural and Biological Sciences4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPubMedEmbaseCASPublisher website
Other: Google Scholar, Crossref, KoreaMed, KoreaMed Synapse, KoMCI
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 2.8LetPub ·
- SJR 2026-06
- 0.4LetPub ·
- SNIP 2026-06
- 0.44LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 163OpenAlex ·
- 2-year mean citedness
- 2.27OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 41LetPub ·
Articles by year OpenAlex count · 423 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 19 | 19 | 4 |
| 2025 | 47 | 47 | 89 |
| 2024 | 38 | 38 | 143 |
| 2023 | 42 | 42 | 155 |
| 2022 | 39 | 39 | 344 |
| 2021 | 40 | 40 | 516 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
43 daysMedian, submission to acceptance · P25–P75 21 days – 98 days
- Acceptance to online
- median 29 days (61 articles)
- Submission to online
- median 79 days
- Sample
- 61 articles with submission and acceptance dates (63 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≤ 5
- Manuscript length
- ≤ 1,200 words
- Reference style
- Vancouver
- Cover letter
- Required
Article types accepted8, with length limits
- brief communicationAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…main text ≤ 100 words · abstract ≤ 100 words
- case reportAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…main text ≤ 200 words · abstract ≤ 200 words
- commentaryAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…Length not stated
- correspondenceAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…Length not stated
- editorialAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…main text ≤ 1,200 words
- letterAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…Length not stated
- reviewAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…Length not stated
- review articleAll other types of manuscripts should meet the above-mentioned requirements. Review articles Review articles should focus on a specific topic. Publication of th…main text ≤ 200 words · abstract ≤ 200 words
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Open access, Peer review, Plagiarism
- Authorship Authorship
Clin Exp Vaccine Res follows the recommendations for authorship by the ICMJE (2013, http://www.icmje.org) and the Good Publication Practice Guidelines by the KAMJE (2013, http://www.kamje.or.kr/intro.php?body=publishing_ethics). The uniform requirements by the ICMJE recommends authorship as follows. Authorship credit should be based on 1) substantial contributions to conception and design, acquisi…
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
The corresponding author of an article is asked to inform the Editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A potential conflict of interest should be disclosed in the cover letter even when the authors are confident that their judgments have not been influenced in preparing the manuscript. Such conflicts may be financial support or priva…
Source ↗Publisher website ·- Open access Open Access Policy: Proprietary Rights Notice for Clin Exp Vaccine Res Online
The person using Clinical and Experimental Vaccine Research Online may use, reproduce, disseminate, or display the open access version of content from this journal for non-commercial purposes. Any use of the open access version of this Journal in whole or in part must include the customary bibliographic citation, including author and publisher attribution, date, article title, Clin Exp Vaccine Res…
Source ↗Publisher website ·- Peer review Editorial and Peer Review Process
Clin Exp Vaccine Res reviews all manuscripts received. A manuscript is first reviewed for its format and then sent to the 3 most relevant investigators of the relevant field available for review of the contents. The editor selects peer referees by recommendation of the editorial and review board members. In addition, if deemed necessary, a review of statistics may be requested. Authors' names and …
Source ↗Publisher website ·- Plagiarism Redundant Publication and Plagiarism
Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)”. Characteristics of reports that are substantially similar include the following: (a) at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant pub…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Seoul : Korean Vaccine Society
- Country or region
- Korea, Republic of
- Language
- English
- ISSN
- 2287-3651
- Electronic ISSN
- 2287-366X
- Society / sponsor
- Korean Vaccine Society
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Clinical and Experimental Vaccine Research
What CAS zone is Clinical and Experimental Vaccine Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical and Experimental Vaccine Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Clinical and Experimental Vaccine Research?
Based on the dates recorded on 61 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 43 days (interquartile range 21–98 days); authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical and Experimental Vaccine Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≤ 5; Manuscript length: ≤ 1,200 words; Reference style: Vancouver; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical and Experimental Vaccine Research based?
Of the 49 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are South Korea (30), United States (8) and Japan (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical and Experimental Vaccine Research?
According to LetPub and DOAJ records, Clinical and Experimental Vaccine Research is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC, PubMed, Embase and CAS; that list has not been checked against each database.
Is Clinical and Experimental Vaccine Research open access, and what is the APC?
Clinical and Experimental Vaccine Research is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .